REG - Oxford Biomedica PLC - PDMR / PCA Dealing

Oxford BioMedicaAnnouncement

27/09/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230927:nRSa8662Na&default-theme=true

RNS Number : 8662N  Oxford Biomedica PLC  27 September 2023

 

 

PDMR / PCA Dealing

 

Oxford, UK - 27 September 2023: Oxford Biomedica plc ("Oxford Biomedica" or
" the Company") (LSE:OXB), a quality and innovation-led viral vector CDMO,
today announces that Sandra Juliet Ferera Hayden, a person closely associated
with Michael Hayden, a Non-Executive Director of the Company, purchased
ordinary shares in the Company yesterday.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the number of ordinary shares
purchased.

 

 1.  Details of the Person Closely Associated ("PCA")
 a)  Name                                     Sandra Juliet Ferera Hayden
 2.  Reason for the notification
 a)  Position/status                          This notification concerns Sandra Juliet Ferera Hayden in her capacity as a
                                              person closely associated with a person discharging managerial
                                              responsibilities. The person discharging managerial responsibilities is
                                              Michael Hayden, a Non-Executive Director at the Company. The association
                                              arises by virtue of Sandra Juliet Ferera Hayden being the spouse of Mr.
                                              Hayden.

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £2.935    12,000

 e)  Aggregated information

     -    Aggregate volume                    12,000

     -    Aggregated total

                                              £35,220
 f)  Date of the transaction                  2023-09-26
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

12,000

 

 

£35,220

f)

Date of the transaction

2023-09-26

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , www.oxbsolutions.com
(https://oxbsolutions.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUMABUPWGUM